6-Month Outcomes of the TricValve System in Patients With Tricuspid Regurgitation: The TRICUS EURO Study

• Published in: JACC. Cardiovascular interventions 2022-07, Vol.15 (13), p.1366-1377
• Main Authors: Estévez-Loureiro, Rodrigo, Sánchez-Recalde, Angel, Amat-Santos, Ignacio J, Cruz-González, Ignacio, Baz, Jose A, Pascual, Isaac, Mascherbauer, Julia, Abdul-Jawad Altisent, Omar, Nombela-Franco, Luis, Pan, Manuel, Trillo, Ramiro, Moreno, Raul, Delle Karth, Georg, Salido-Tahoces, Luisa, Santos-Martinez, Sandra, Núñez, Jean C, Moris, Cesar, Goliasch, Georg, Jimenez-Quevedo, Pilar, Ojeda, Soledad, Cid-Álvarez, Belén, Santiago-Vacas, Evelyn, Jimenez-Valero, Santiago, Serrador, Ana, Martín-Moreiras, Javier, Strouhal, Andreas, Hengstenberg, Christian, Zamorano, Jose Luis, Puri, Rishi, Íñiguez-Romo, Andrés
• Format: Article
• Language: English
• ISSN: 1876-7605
• DOI: 10.1016/j.jcin.2022.05.022

BACKGROUNDSevere tricuspid regurgitation (TR) is frequently associated with significant morbidity and mortality; such patients are often deemed to be at high surgical risk. Heterotopic bicaval stenting is an emerging, attractive transcatheter solution for these patients. OBJECTIVESThe aim of this study was to evaluate the 30-day safety and 6-month efficacy outcomes of specifically designed bioprosthetic valves for the superior and inferior vena cava. METHODSTRICUS EURO (Safety and Efficacy of the TricValve® Transcatheter Bicaval Valves System in the Superior and Inferior Vena Cava in Patients With Severe Tricuspid Regurgitation) is a nonblinded, nonrandomized, single-arm, multicenter, prospective trial that enrolled patients from 12 European centers between December 2019 and February 2021. High-risk individuals with severe symptomatic TR despite optimal medical therapy were included. The primary endpoint was quality-of-life (QOL) improvement measured by Kansas City Cardiomyopathy Questionnaire score and New York Heart Association (NYHA) functional class improvement at 6-month follow-up. RESULTSThirty-five patients (mean age 76 ± 6.8 years, 83% women) were treated using the TricValve system. All patients at baseline were in NYHA functional class III or IV. At 30 days, procedural success was 94%, with no procedural deaths or conversions to surgery. A significant increase in QOL at 6 months follow-up was observed (baseline and 6-month Kansas City Cardiomyopathy Questionnaire scores 42.01 ± 22.3 and 59.7 ± 23.6, respectively; P = 0.004), correlating with a significant improvement in NYHA functional class, with 79.4% of patients noted to be in functional class I or II at 6 months (P = 0.0006). The rates of 6-month all-cause mortality and heart failure hospitalization were 8.5% and 20%, respectively. CONCLUSIONSThe dedicated bicaval system for treating severe symptomatic TR was associated with a high procedural success rate and significant improvements in both QOL and functional classification at 6 months follow-up.